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CONSPECTUS: Artiﬁcial metalloenzymes (ArMs) result
from anchoring a metal-containing moiety within a macro-
molecular scaﬀold (protein or oligonucleotide). The resulting
hybrid catalyst combines attractive features of both homoge-
neous catalysts and enzymes. This strategy includes the
possibility of optimizing the reaction by both chemical
(catalyst design) and genetic means leading to achievement
of a novel degree of (enantio)selectivity, broadening of the
substrate scope, or increased activity, among others. In the
past 20 years, the Ward group has exploited, among others,
the biotin−(strept)avidin technology to localize a catalytic
moiety within a well-deﬁned protein environment. Streptavi-
din has proven versatile for the implementation of ArMs as it
oﬀers the following features: (i) it is an extremely robust protein scaﬀold, amenable to extensive genetic manipulation and
mishandling, (ii) it can be expressed in E. coli to very high titers (up to >8 g·L−1 in fed-batch cultures), and (iii) the cavity
surrounding the biotinylated cofactor is commensurate with the size of a typical metal-catalyzed transition state. Relying on a
chemogenetic optimization strategy, varying the orientation and the nature of the biotinylated cofactor within genetically
engineered streptavidin, 12 reactions have been reported by the Ward group thus far. Recent eﬀorts within our group have
focused on extending the ArM technology to create complex systems for integration into biological cascade reactions and in
vivo.
With the long-term goal of complementing in vivo natural enzymes with ArMs, we summarize herein three complementary
research lines: (i) With the aim of mimicking complex cross-regulation mechanisms prevalent in metabolism, we have
engineered enzyme cascades, including cross-regulated reactions, that rely on ArMs. These eﬀorts highlight the remarkable
(bio)compatibility and complementarity of ArMs with natural enzymes. (ii) Additionally, multiple-turnover catalysis in the
cytoplasm of aerobic organisms was achieved with ArMs that are compatible with a glutathione-rich environment. This feat is
demonstrated in HEK-293T cells that are engineered with a gene switch that is upregulated by an ArM equipped with a cell-
penetrating module. (iii) Finally, ArMs oﬀer the fascinating prospect of “endowing organometallic chemistry with a genetic
memory.” With this goal in mind, we have identiﬁed E. coli’s periplasmic space and surface display to compartmentalize an ArM,
while maintaining the critical phenotype−genotype linkage. This strategy oﬀers a straightforward means to optimize by directed
evolution the catalytic performance of ArMs. Five reactions have been optimized following these compartmentalization
strategies: ruthenium-catalyzed oleﬁn metathesis, ruthenium-catalyzed deallylation, iridium-catalyzed transfer hydrogenation,
dirhodium-catalyzed cyclopropanation and carbene insertion in C−H bonds. Importantly, >100 turnovers were achieved with
ArMs in E. coli whole cells, highlighting the multiple turnover catalytic nature of these systems.
1. INTRODUCTION
Biology relies on a set of bioavailable elements and cofactors to
catalyze a variety of chemical transformations. Biosynthesis is
ﬁne-tuned and regulated, allowing for multistep synthesis
without the need for isolation of intermediates or protecting
groups. In contrast, chemists are able to access non-
bioavailable elements and molecules to develop catalysts.
Multistep synthesis, however, often requires isolation of
intermediates and use of protecting groups. Merging features
of synthetic and biological catalysts could provide beneﬁts for
both biology and chemistry. Inserting synthetic catalysts into
biological systems could expand the repertoire of reactions
available in biology, giving access to new biocatalysts.
Additionally, instilling catalysts with regulatory features
prevalent in biology may enable cascades that are often not
possible with synthetic catalysts. Introduction of catalysts into
a biological context can be challenging for several reasons: (i)
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homogeneous catalysts are often intolerant toward oxygen,
water, or both, (ii) cross-reactivity of synthetic catalysts and
biomolecules can lead to mutual deactivation,1 and (iii)
synthetic catalysts often perform best in organic solvents. Some
of these limitations may be circumvented by compartmentaliz-
ing the catalyst within a protein environment.2,3
In biology, catalytic cofactors are often protected from the
surrounding media by scaﬀolding within a protein. Borrowing
from this methodology, homogeneous catalysts can be
anchored into a protein to aﬀord artiﬁcial metalloenzymes
(ArMs). ArMs may combine advantageous features of
organometallic and enzymatic catalysts, providing a means
for designing new-to-nature biocatalysts and incorporating
synthetic catalysts into cascades. Using this approach, our
group has exploited streptavidin (SAV) as a scaﬀold. These
SAV-based ArMs have been optimized to catalyze a variety of
organic transformations, summarized in previous reviews.4−6
Building on this experience, recent work has focused on
addressing new challenges: (i) the creation of new cascades,
(ii) mimicking cross-regulation by combining ArMs with
enzymes, and (iii) directed evolution of ArMs. By building
upon these eﬀorts in our future work, our ultimate aim is to
create new biocatalytic networks and metabolic pathways in
vivo.
2. ARTIFICIAL METALLOENZYME-DRIVEN
ENZYMATIC CASCADES
Cascades involve the combination of two or more concomitant
reactions in a single vessel without isolation of intermediates.7,8
Although cascades are less common in synthetic chemistry,
Nature relies on cascades to produce its metabolites. This feat
is achieved by enzymes that have evolved to operate in
complex mixtures. One advantage of enzymes is that the active
site is often protected by the surrounding amino acids. This
prevents undesired cross-reactivity or catalyst poisoning. We
reasoned that to engineer cascades, SAV-based ArMs may
provide an attractive tool. Protecting a catalyst upon
incorporation within SAV reduces unwanted side reactions
and prevents inhibition.9
In our previous Accounts,5,6 we summarized our eﬀorts
toward the development of an artiﬁcial transfer hydrogenase
for the reduction of imines (ATHase). The cofactor was
composed of a d6-piano-stool complex bearing an amino-
sulfonamide or aminoamide ligand. These ATHases required
molar concentrations of formate, precluding their use in vivo.
With our aim of developing in vivo cascades, we set out to
identify a biocompatible hydride source.
2.1. An NADPH-Dependent Artiﬁcial Transfer
Hydrogenases for Multienzymatic Cascades
Inspired by Nature, we selected the NAD(P)+/NAD(P)H
couple (and mimics thereof) and evaluated their compatibility
with ATHases based on the biotin−streptavidin technology.10
Initial studies focused on NAD+ mimics, which were shown to
act as hydride source with ene-reductases from the Old Yellow
Enzyme (OYE) family.11 A two-enzyme cascade was
assembled by combining an ATHase with an ene-reduc-
tase.10,12 By ﬁne-tuning the reaction conditions to minimize
the reduction of the enoate by the ATHase,13 the NAD+ mimic
could be recycled by the ATHase using formate as a terminal
Scheme 1. Enzyme Cascades Using ATHasesa
a(a) Catalytic reduction of enones by ene reductase and catalytic NAD+ regeneration by [Cp*Ir(Biot-p-L)Cl]·SAV. (b) Cofactor and
corresponding ATHase: [(Biot-Cp*)Ir(phen(OH)2)Cl]·SAV. (c) Four enzyme cascade for the reduction of cyclic imines using glucose as terminal
reductant.
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reductant. The resulting cascade led to the production of cyclic
ketones and lactones in high ee (91−93%), Scheme 1a.
We hypothesized that it may be possible to utilize
NAD(P)H as a hydride source for the ATHase. For the
regeneration of NADP+, we selected glucose dehydrogenase
(GDH), an enzyme that converts glucose into gluconolactone,
thereby reducing NADP+ to NADPH. To identify the most
suitable biotinylated d6-piano-stool complex that accepts a
hydride from NADPH, we screened bidentate ligands in
combination with either Rh(III) or Ir(III) bearing a
biotinylated cyclopentadienyl moiety (Biot−Cp*, Scheme
1b). This allowed us to screen bidentate ligands without
biotinylating each ligand prior to screening.14 Among the 27
bidentate ligands tested, 4,7-dihydroxy-1,10-phenanthroline
(phen(OH)2) was the best candidate for the reduction of 1-
methyl-3,4-dihydroisoquinoline (MDQ) to 1-methyl-1,2,3,4-
tetrahydroisoquinoline (MTQ), Scheme 1c.15 An enzyme
cascade was assembled by combining GDH and the ATHase,
enabling reduction of MDQ using glucose as reductant. The
performance of the ATHase was ﬁne-tuned by screening a
focused library of SAV mutants: [(Biot−Cp*)Ir(phen(OH)2)-
Cl]·SAV K121R displayed a 5-fold higher turnover compared
to WT SAV ATHase. To upgrade the enantioselectivity (<20%
ee in favor of (R)-MTQ), an (S)-selective monoamine oxidase
(MAO) was added to the cascade. A catalase (from bovine
liver) ensured the rapid disproportionation of H2O2 produced
by the MAO. With this four-enzyme cascade, full conversion
with >99% ee was achieved, using only two equivalents of
glucose.
Scheme 2. Temporally Programmed Reduction of Enroﬂoxacina
a(a) Both the ATHase and urease are reversibly inhibited at basic pH. The activity of the urease leads to inhibition of the ATHase, which is
restored by acidiﬁcation, acting as fuel to drive both reactions. (b) Reaction progress (violet) as a function of pH. Adapted from ref 16. Copyright
2017 John Wiley & Sons.
Scheme 3. Engineering a Third Coordination Sphere around Biotinylated Metal Cofactors by Inclusion within Ferritina
a(a) Metal distribution of SAV-based ArMs from X-ray. (homotetrameric SAV is displayed as surface, residues S112 and K121 of adjacent SAV
monomers forming the biotin-binding vestibule are highlighted in tan; the metals from the biotinylated Ir (yellow, PDB codes 6GMI, 6ESS, 6ESU,
4OKA, and 3PK2), Rh (orange, PDB codes 4GJV and 4GJS), Ru (magenta, PDB codes 6FH8, 5F2B, 5IRA, 2QCB, and 2WPU), Cu (blue, PDB
codes 5VKX, 5VL5, 5VL8, 5WBA, 5WBB, 5WBD, 6ANX, 5WBC, 5K67, 5K68, and 5L3Y) and Pd (green, PDB code 5CSE) cofactors are
represented by spheres (only one metal per SAV dimer displayed). (b) Slice through the docked structure of [Cp*Ir(Biot-p-L)Cl]·SAV (PDB code
3PK2, dimensions 4.5 nm × 5.5 nm × 5.1 nm) encapsulated within ferritin (slice through the surface display (brown shell), PDB code 5C6F). (c)
Cartoon representation for [Cp*Ir(Biot-p-L)Cl] and ATHase (see Scheme 1 for details). (d) Results of ATHase encapsulated within ferritin.
Positive ee, (R)-products; negative ee, (S)-products.
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2.2. Enzymatic Regulation of a pH-Programmed ATHase
Metabolic pathways are tightly (cross-)regulated by enzymes
that balance the equilibrium of a myriad of reactions required
to sustain life. In vivo, metabolic pathways are responsive to
chemical and physical stimuli. A pathway can be turned on or
oﬀ to provide cells with necessary resources on demand,
limiting the waste of precious metabolic resources. Engineering
cross-regulated pathways is challenging but provides a
mechanism for regulating catalysis. To address this challenge,
we designed a reversible pH-trigger for an ATHase.16 The
activity of the ATHase [(Biot−Cp*)Ir(phen(OH)2)Cl]·SAV
K121R is regulated by urease in a pH-responsive fashion,
mimicking cross-regulated networks.16 Enroﬂoxacin (1) was
selected as substrate as, upon reduction and decarboxylation,
the yellow ketone 2 is produced, which can be monitored
spectrophotometrically (Scheme 2a).
Initial studies revealed that the reduction of enroﬂoxacin by
the ATHase [(Biot−Cp*)Ir(phen(OH)2)Cl]·SAV K121R
exhibits pH-dependent behavior and proceeds under acidic
but not basic conditions. Restoration of ATHase activity is
observed upon addition of HCl (pH < 6.0) to a stalled alkaline
solution. We reasoned that the pH of the solution may be
regulated by urease (from Canavalia ensiformis) that hydrolyzes
urea to NH3 and CO2, leading to alkalization. Compartmen-
talization of the cofactor within SAV is essential for both
enzymes to coexist: in the absence of SAV, both [(Biot−
Cp*)Ir(phen(OH)2)H] and urease suﬀer from inactivation.
An ATHase and urease mixture containing their respective
substrates (urea and enroﬂoxacin) was prepared at pH = 9.
Upon lowering the pH to below 6.5, the two enzymes are
activated; both the pH and the formation of 2 can be
monitored. The formation of 2 is observed in the acidic
regime, but gradual increase in pH caused by the production of
ammonia inhibits the reaction above pH ∼ 7. Addition of HCl
readily restores both enzymatic activities (Scheme 2b).
The addition of HCl can be circumvented by incorporating
an esterase. We envisioned that ethyl butyrate could act as a
dormant activator, as it is converted to butyric acid by an
esterase (Scheme 2a). As predicted, addition of an esterase to a
mixture at pH > 8 consisting of [(Biot−Cp*)Ir(phen(OH)2)-
H]·SAV K121R, urease, enroﬂoxacin, urea, and ethyl butyrate
causes a pH decrease, and product formation is detected when
an acidic pH is reached. Product formation continues until
basic pH is reached.
3. COMPARTMENTALIZATION OF ARTIFICIAL
METALLOENZYMES IN MORE COMPLEX
STRUCTURES
Interactions between the protein and the substrate lead to
precise positioning and rapid turnover. From the >20
structurally characterized SAV-based ArMs, the cofactor
resides in a narrow dispersion, tweezed between S112 and
K121 SAV residues (Scheme 3a). These two residues are often
our prime choice for genetic optimization. Despite the
undeniable power of this methodology, it does not allow for
large perturbations of the ArM’s active site owing to the
rigidity of the protein scaﬀold and shallow topology of the
biotin binding vestibule (Scheme 3a). In eﬀorts to engineer a
more buried active site, we encapsulated an ArM within a
protein host to provide the cofactor with a third coordination
sphere: the biotinylated ligand and SAV providing the ﬁrst-
and second-coordination spheres, Scheme 3b.
3.1. Ferritin as a Tertiary Coordination Sphere
The ferritin family of iron-storage proteins have long been
exploited for biotechnological applications.17 Ferritin com-
prises 24 monomers that form a ∼7−8 Å spherical cage, which
encapsulate, store, and traﬃc ∼2400 Fe atoms (as Fe/OH/
PO4).
17 The reversible formation of apoferritin is achieved
upon acidiﬁcation and neutralization. The encapsulation of a
Scheme 4. Artiﬁcial Metalloenzyme Upregulates a Gene Circuit in Mammalian Cellsa
a(a) The catalyst [CpRu(Biot-QuinCO2)H2O] is combined within SAV with a biotinylated cell-penetrating disulﬁde CPD equipped with a
ﬂuorescent reporter (TAMRA). The cell-penetrating ArM enters the designer HEK-293T cell by covalent-mediated disulﬁde exchange.27 (b) The
doubly-caged hormone AM-AT3 is hydrolyzed to AT3 by endogeneous esterases. The O-allylcarbamate moiety is hydrolyzed in vivo by the cell-
penetrating ArM to aﬀord T3. (c) The designer HEK-293T cells are equipped with a gene circuit to respond to the T3-hormone, leading to the
bioluminescent production of 8 from furimazine. The cell’s viability is monitored by the formation of p-nitrophenolate produced by a constitutively
expressed alkaline phosphatase. Adapted with permission from ref 22. Copyright 2018 Nature Publishing Group.
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commensurate cargo is achieved upon refolding ferritin in the
presence of the cargo.
We incorporated [Cp*Ir(Biot-p-L)Cl]·SAV into apoferritin
to probe the eﬀect of ferritin on ATHase activity (Scheme
3d).18 Access of the protonated substrates 3 or 5 to the
ATHase was facilitated by the ferritin 3-fold channels that
direct cationic substrates to the interior. The encapsulation of
the [Cp*Ir(Biot-p-L)Cl]·SAV@ferritin altered product distri-
bution and catalytic performance. In the absence of ferritin,
[Cp*Ir(Biot-p-L)Cl]·SAV S112A leads to the (R)-4 (75% ee
and 142 TON). In contrast, [Cp*Ir(Biot-p-L)Cl]·SAV@
ferritin aﬀords preferentially (S)-4. For the most active
ATHase, [Cp*Ir(Biot-p-L)Cl]·SAV S112A−K121A,19 encap-
sulation enhances the TON for substrate 6 (TON = 289 vs
3874 for the free and encapsulated ATHases, respectively).
These data highlight the inﬂuence the tertiary coordination
sphere on the performance of ArMs. Failure to structurally
characterize [Cp*Ir(Biot-p-L)Cl]·SAV@ferritin by X-ray
points toward a high degree of disorder of the ATHase within
ferritin. A crystal structure of ferritin (PDB 5C6F)20 allowed us
to model [Cp*Ir(Biot-p-L)Cl]·SAV@ferritin (Scheme 3b).
3.2. Artiﬁcial Metalloenzyme That Regulates a Gene
Switch in Mammalian Cells
Whole-cell catalysis has received increasing attention as it
oﬀers the possibility to combine abiotic reactions with
metabolic pathways. Artiﬁcial metalloenzymes may provide
versatile tools toward this endeavor. Although several examples
involving organometallic catalysis within E. coli or mammalian
cells have been reported,21 rarely is there a productive
cooperation between the cellular environment and the abiotic
reaction that leads to activation of cellular function.
We thus set out to upregulate the expression of a reporter
protein in response to an ArM (Scheme 4). The ArM produces
a bioactive molecule that triggers the transcription of a gene
that can be visualized by the production of a bioluminescent
marker. Several factors need to be addressed to ensure the
orchestration of this cascade: (i) eﬃcient uptake of ArMs by
mammalian cells and subsequent monitoring of ArM local-
ization (Scheme 4a); (ii) engineering of a gene switch that is
regulated by the product of the ArM-catalyzed reaction,
resulting in (iii) a luminescent readout (Scheme 4c).22
(i) Inspired by Meggers’ ruthenium catalyst for uncaging of
an O-allyl carbamate in vivo,23 we synthesized a biotinylated
analog Biot-QuinCO2 for assembly with SAV. In vitro genetic
optimization led us to select [CpRu(Biot-QuinCO2)H2O]·
SAV S112A for the O-allyl carbamate cleavage of AT3. To
overcome modest cellular uptake of related organometallic
complexes,24,25 we combined it with a cell-penetrating module.
Thanks to the homotetrameric nature of SAV, we coassembled
[CpRu(Biot-quinCO2)H2O] with a biotinylated cell-penetrat-
ing moiety. We selected a cell-penetrating poly(disulﬁde)
(CPD), developed by Matile.26 The CPD contains a
ﬂuorescent TAMRA moiety that allows real-time monitoring
of the cellular uptake and distribution of the fully assembled
ArM. To favor the uptake of the O-allylcarbamate-caged
thyroid hormone AT3, we esteriﬁed it to AM-AT3 (these are
readily saponiﬁed by endogeneous esterases in mammalian
cells).
(ii) The HEK-293T cells were engineered with a T3-
responsive gene switch, consisting of genes encoding a
synthetic T3-thyroid hormone receptor (TSR) and a Gal4-
speciﬁc operator sequence under the control of a minimal
promoter that induces the expression of a secreted nanoluc
(sec-nluc), a bioluminescence reporter. In the presence of T3,
the TSR recruits coactivators, triggering histone acetylation to
initiate sec-nluc expression. The last step can be monitored by
the luminescent conversion of furimazine 7 into product 8. To
highlight cell-viability, an alkaline phosphatase (SEAP) was
coexpressed constitutively, leading to the formation p-nitro-
phenolate 10 by hydrolysis of p-nitrophenylphosphate (9,
Scheme 4).
(iii) The HEK-293T cells, transfected with the T3-
responsive gene switch, were treated with [CpRu(Biot-
QuinCO2)H2O]·SAV S112A. Introduction of the ArM caused
an increase in ﬂuorescence as revealed by confocal microscopy
and ﬂow cytometry, conﬁrming the ArM’s uptake. After
incubation and washing, the substrate AM-AT3 was added. The
luminescence caused by the gene switch was signiﬁcantly
higher in the presence of [CpRu(Biot-QuinCO2)H2O]·SAV
S112A than either with the free cofactor or with no cofactor at
all. The ArM devoid of its CPD moiety also gave much lower
luminescence. These observations conﬁrm that only cell-
penetrating ArMs lead to the uncaging of AT3 in vivo,
highlighting the importance of membrane permeability. The
constitutive expression of an alkaline phosphatase allowed us
to monitor the viability of the engineered HEK-293T cells
throughout the entire process.
4. COMPARTMENTALIZATION AND SURFACE
DISPLAY OF ArMS: VERSATILE PLATFORMS FOR
DIRECTED EVOLUTION OF ArMS IN LIVING CELLS
4.1. Introduction
With the goal of optimizing ArMs through directed evolution,
we sought to create a screening platform for ArM activity.
Although some catalysts are active in vivo, most notably the
[CpRuL3]-based systems developed by Meggers,
23−25,28 many
precious-metal catalysts are irreversibly poisoned in the
cell.29−31 This deactivation is primarily caused by thiols,
most notably glutathione.31 Previous work with cell-free
extracts revealed that diamide oxidizes glutathione, preventing
poisoning of iridium catalysts.31 Implementation of this
diamide strategy allowed for optimization by directed
evolution of an artiﬁcial imine reductase, using cell free
extracts.32 The scope of this strategy, however, is limited
because (i) diamide is incompatible with some catalysts and
(ii) the method is signiﬁcantly more laborious than traditional
in vivo evolution methods, limiting the number of variants that
can be practically screened. Alternatively, sequestration of
ArMs into chemically distinct compartments oﬀers the
opportunity to minimize catalyst poisoning. Two convenient
methods of compartmentalization are available for E. coli:
periplasmic secretion and surface display. Each of these
methods presents advantages and disadvantages, Scheme 5.
Unlike the cytoplasm, the periplasm is slightly oxidizing and
contains signiﬁcantly less glutathione (GSH).34 In addition,
GSH in the periplasm exists mostly in it oxidized form, GSSG,
which is less deleterious for both ruthenium and iridium
catalysts.29,31 Surface display leads to anchoring of the protein
to the outer membrane, signiﬁcantly reducing exposure to
thiols.
In addition to sequestering the catalyst, it was posited that
these methods might aﬀord higher access of the substrate and
the abiotic cofactor required for ArM assembly. To accumulate
in the cytoplasm, the cofactor must transit through the outer
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membrane and the less-permeable inner membrane of E. coli.
Exporting the ArM scaﬀold to the periplasm eliminates the
need for the cofactor to cross the inner membrane.
Implementing the surface-display method provides even
greater accessibility.
Both periplasmic secretion and surface display retain the
phenotype−genotype linkage required for directed evolution.
With these features in mind, we assessed the utility of both
these methods for directed evolution of ArMs.
4.2. Directed Evolution of a Metathase Facilitated by
Compartmentalization in E. coli’s Periplasm
We reported the directed evolution of a periplasm-localized
ArM for oleﬁn metathesis (metathase).29 Although oleﬁn
metathesis is ubiquitously used in organic synthesis, there is no
equivalent in Nature. Ru-based metathesis catalysts oﬀer
auspicious tools for the creation of ArMs because they are
water and oxygen tolerant.35−37 However, Ru-based metathesis
catalysts are sensitive to GSH, either in the presence or in the
absence of SAV.30
To create a periplasm-compartmentalized ArM scaﬀold, we
modiﬁed SAV for periplasmic secretion (Scheme 6). This
engineered SAV (SAVperi) contained a short, nine amino acid,
N-terminal peptide sequence (OmpA). Upon secretion by the
SEC pathway, the OmpA tag is cleaved providing untagged
SAV.38 Periplasmic fractionation and ﬂuorescent staining
conﬁrmed that SAVperi was secreted to the periplasm and
maintained its biotin-binding activity.
The biotinylated metathesis cofactor [RuCl2(Biot−NHC)-
(styr)] consists of a biotin linked to an Hoveyda−Grubbs
second-generation catalyst. ICP-OES of cell fractions con-
ﬁrmed that [RuCl2(Biot−NHC)(styr)] diﬀuses through the
outer membrane and accumulates in the periplasm. When
SAVperi is present, the concentration of [RuCl2(Biot−NHC)-
(styr)] in the periplasm increases 3-fold. To examine the
activity of the [RuCl2(Biot−NHC)(styr)]·SAVperi, the umbel-
liferone precursor 11 and [RuCl2(Biot−NHC)(styr)] were
incubated with cells lacking or expressing SAVperi (Scheme 6b).
Cells expressing SAVperi catalyzed the ring-closing metathesis
(RCM) reaction of oleﬁn 11 to yield ﬂuorescent umbelliferone
(12). Quantiﬁcation of metathase activity was determined by
ﬂuorescence. In the absence of SAVperi, negligible metathesis
activity was observed in cells. Accordingly, the observed
reactivity is attributed to the assembled metathase, enabling
quantiﬁcation with minimal background from the unbound
[RuCl2(Biot−NHC)(styr)] cofactor. Thus, we implemented a
Scheme 5. Strategies for Compartmentalization of ArMs in
E. colia
aThe ArM scaﬀolds (blue, only one monomer displayed) can be
localized in the cytoplasm, in the periplasm, or on the surface.
Cytoplasmic expression results in high protein expression but reduces
accessibility of the substrate and metal cofactor. Additionally, the
cytoplasmic environment is rich in thiols. In contrast, surface display
of the ArM scaﬀold decreases expression level but favorably increases
cofactor and substrate accessibility and decreases exposure of the ArM
to thiols. Catalysis within the periplasm provides a good compromise
in terms of expression level, accessibility, and thiol concentration.
Adapted with permission from ref 33. Copyright 2016 Academic
Press.
Scheme 6. Metathase Compartmentalized in the Periplasm of E. colia
a(a) Cytoplasmic expression of SAVperi (displayed as a monomer for clarity) is followed by secretion to the periplasm. In the periplasm, the OmpA
tag is hydrolyzed, and the homotetrameric SAVperi binds to [RuCl2(Biot−NHC)(styr)], aﬀording the metathase that converts 11 to ﬂuorescent
umbelliferone, 12. (b) In vivo activity of the cofactor [RuCl2(Biot−NHC)(styr)] in the absence (SAV−) and presence of SAVperi. Adapted with
permission from ref 29. Copyright 2016 Nature Research.
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protocol for directed evolution based on ﬂuorescent screening
of SAVperi mutant libraries in E. coli (Scheme 7a).
The screening platform enables rapid 96-well plate analysis
of single clones. In this workﬂow, the DNA library is
transformed into chemically competent E. coli. For library
screening, Top10 cells were selected because they provide the
optimal combination of high transformation eﬃciency and
eﬃcient secretion of OmpA-tagged proteins to the periplasm.
DNA libraries were designed for single-site-saturation
mutagenesis of the 20 residues closest to the Ru atom based
on a docking model of [RuCl2(Biot−NHC)(styr)] with WT
SAV. A single mutation at 14 of the 20 proximal residues
yielded an advantageous mutant. Iterative saturation muta-
genesis39 at these 14 residues resulted in a mutant with a 5-fold
increased activity with 11 using [RuCl2(Biot−NHC)(styr)]·
SAVmut (SAVmut = SAV V47A/N49K/T114Q/A119G/
K121R).
After directed evolution for metathesis using 11, we
evaluated the substrate scope of the evolved metathase
[RuCl2(Biot−NHC)(styr)]·SAVmut, using puriﬁed SAVmut.
Scheme 7. Optimization of a Metathase through Iterative Saturation Mutagenesisa
a(a) Schematic workﬂow of the ﬂuorescence-based assay for periplasm-localized ArMs. (b) Cell-speciﬁc activity allows identifying advantageous
mutations obtained during iterative saturation mutagenesis. (c) Structural characterization of the ﬁfth-generation metathase (PDB 5F2B). The
asterisks highlight amino acids on the adjacent monomer. (d) Ring-closing metathesis activity of puriﬁed metathases towards substrates 2,2-diallyl-
1,3-propanediol (13) and diallyl-sulfonamide (15). Adapted with permission from ref 29. Copyright 2016 Nature Research.
Scheme 8. Surface Displayed Artiﬁcial Deallylasea
aAssembly of the deallylase on the cell surface (single monomer of SAVSD depicted). SAVSD is displayed on the surface enabling facile assembly of
the ArM. Once the deallylase is assembled, there is unencumbered access of the allyl-protected substrate 17. The deallylase converts 17 to the
ﬂuorescent product 18. Adapted with permission from ref 42. Copyright 2018 Royal Society of Chemistry.
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The activity was assessed with two substrates: 2,2-diallyl-1,3-
propanediol (13) and a cationic diallyl-sulfonamide 15,
Scheme 7d. RCM of 13 yielded the highest turnover with
[RuCl2(Biot−NHC)(styr)]·SAVmut. Turnover for 15 was
higher with WT SAV than with [RuCl2(Biot−NHC)(styr)]·
SAVmut. We hypothesize that the positively charged 121R
residue within the evolved active site may prevent eﬃcient
turnover with the cationic substrate.
To identify a metathase for cationic substrates, a second
round of directed evolution of SAVmut was conducted with 15.
The positively charged residue K121R of SAVmut was
randomized. Screening with 15 was adapted to replace
ﬂuorescence detection with LC-MS analysis. The UPLC-MS-
based screening revealed that [RuCl2(Biot−NHC)(styr)]·
SAVmut2 (V47A/N49K/T114Q/A119G/K121L) yielded the
highest TON for the cationic substrate. The SAVmut2 host
performed worse than SAVmut for the neutral substrates 11 and
13, suggesting that the mutation is only beneﬁcial for the
cationic substrate. These results indicate that a rapid
ﬂuorescent screening platform can provide a highly valuable
starting point for slower LC-MS screening platforms. Gratify-
ingly, the RCM activity of both the Hoveyda−Grubbs second
generation and its water-soluble version (Aquamet) with either
substrate 11 or 13 was lower than that obtained in the
presence of [RuCl2(Biot−NHC)(styr)]·SAVmut.
These results provide a novel method for rapid directed
evolution of ArMs in E. coli. This method is amenable to
“substrate walking” allowing access to diverse substrates, with a
limited reoptimization eﬀort. Following the publication of this
work, our group has developed an ArM for carbene transfer40
as well as transfer hydrogenation relying on a self-immolating
iminium substrate41 using a similar periplasmic screening
platform.
4.3. Directed Evolution of an Allylic Deallylase Facilitated
by Surface Display
Surface display also presents a propitious means to protect
ArMs from thiols and to increase accessibility of the substrate
and metal cofactor. Very recently, we reported a strategy for
displaying ArMs on the surface of E. coli (Scheme 8).42 The N-
terminal tag for surface display consists of an Lpp peptide
(amino acids 1−9) and OmpA (46−159) linked to SAV (Lpp-
OmpA-SAV is referred to SAVSD hereafter). Quantitative
export of SAVSD to the extracellular space was conﬁrmed by
antibody-based staining of cells expressing SAV, SAVperi, and
SAVSD. Although the oligomeric state of SAVSD could not be
assessed, other oligomeric proteins form their natural
oligomeric state when expressed on the cell surface.43 Thus,
we assume that SAVSD is likely to be a tetramer when
expressed on the cell surface.
As a proof of concept, this system was used to evolve an
ArM for allylic deallylation (ADAse hereafter) by anchoring
[CpRu(Biot-QuinCO2)H2O] to SAV
SD.42 This [CpRu(Biot-
QuinCO2)H2O] cofactor was selected because the cofactor
catalyzes uncaging at very low catalyst concentrations in
vivo.23,24,28
As a test substrate, the allylcarbamate-protected coumarin
17 was selected. In vitro, the [CpRu(Biot-QuinCO2)H2O]
cofactor catalyzes deprotection of 17 to aﬀord the ﬂuorescent
aminocoumarin (18). To test the catalyst in vivo, cells were
incubated with [CpRu(Biot-QuinCO2)H2O] in the presence
and absence of SAVSD. Expression of WT SAVSD resulted in a
1.5-fold increase in production of 18, which provided an
excellent starting point with limited background from unbound
catalyst.
To assess the functionality of this platform, iterative
saturation mutagenesis was conducted at two sites, (i) K121
and (ii) S112, using the 22-codon trick, previously described
by the Reetz laboratory.44 A ﬂuorescent screening platform,
Scheme 9. Directed Evolution of an ArM for Deallylationa
a(a) Schematic workﬂow of the ﬂuorescence-based screening for surface-displayed ArMs. (b) Cell-speciﬁc activity and TON of puriﬁed mutants.
(c) Structural characterization by X-ray of the most active ADAse resulting from directed evolution (PDB 6FH8, the Cp moiety, in magenta, as well
as the additional solvent ligand were disordered over two positions). Adapted with permission from ref 42. Copyright 2018 Royal Society of
Chemistry.
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adapted from the screening platform used for periplasmic
screening, was implemented (Scheme 9a). The platform for
screening surface-displayed ArMs was amenable to a 96-well
format, but washing the cell pellets before and after catalyst
addition was required to minimize background.
From the ﬁrst round of screening with the K121 library,
three mutants resulted in signiﬁcantly higher activity than WT:
K121S (7.2-fold), K121A (6.4-fold), and K121M (2.6-fold),
Scheme 9b. From these three improved mutants, libraries were
created in which position S112 was randomized by saturation
mutagenesis.44 This second round of mutagenesis resulted in
additional improvements to the activity compared to WT:
S112Y−K121S (25-fold), S112M−K121A (24-fold), and
S112Q−K121M (17-fold).
The best SAV mutants were expressed and puriﬁed for in
vitro catalysis. The activity improvements over WT were
reduced in vitro (Scheme 9b): K121A (2.4-fold), K121S (2.0-
fold), K121M (1.3-fold), S112Y−K121S (4.0-fold), S112M−
K121A (5.7-fold), and S112Q−K121M (1.2-fold). The origin
of these eﬀects may derive from local changes in structure
upon surface display or diﬀerences in the chemical environ-
ment between surface-display and puriﬁed SAV samples. Other
methods for in vivo directed evolution have reported similar
eﬀects.45
X-ray quality crystals of [CpRu(Biot-QuinCO2)H2O]·
S112M−K121A were obtained by crystal soaking the
apoprotein with [CpRu(Biot-QuinCO2)H2O] (Scheme 9c).
The structure highlights a 112Met−π interaction with the
quinoline ring of [CpRu(Biot-QuinCO2)H2O] that stabilizes
the cofactor. Additionally, a pocket for the quinoline ring is
created between the K121A, S112, and L124 from the
neighboring SAV monomer.
Using this surface-display screening method, we have shown
that ArMs could be evolved with only two rounds of iterative
saturation mutagenesis, yielding 25-fold (in vivo) and 5.7-fold
(in vitro) improvements in catalysis. Using the versatile
ﬂuorescent screening platform, more complex directed
evolution campaigns can be envisioned. To this end, our
group is exploring extensive engineering of ArM active sites,
including loop insertions.41,46
5. OUTLOOK
Initiated in 2000, the Ward group has implemented 12 ArMs
relying on the biotin−(strept)avidin technology.4−6 This
contribution summarizes our recent eﬀorts toward in vivo
catalysis and cascade reactions, essential requirements for
applications in synthetic biology and artiﬁcial metabolism.
Toward this goal, both periplasmic secretion and surface
display oﬀer exciting avenues to pursue. Future eﬀorts are
aimed at tailoring the shallow active site to tackle more
challenging reactions that require rigorous control of second
coordination sphere interactions between the substrate and the
catalyst.
We believe that ArMs hold great promise in two
complementary domains: (i) late-stage functionalization of
high-added value drugs, whereby catalyst control is highly
desirable, and (ii) complementation natural enzymes for
synthetic biology applications. In the ﬁrst domain, ArMs,
which are reminiscent of natural enzymes, provide a well-
deﬁned secondary coordination sphere that may be an asset in
overcoming a substrate’s intrinsic reactivity proﬁle. For the
latter domain, the in vivo combination of natural enzymes with
the broad repertoire of homogeneous catalysts will allow us to
use microorganisms as test tubes to produce chemicals or fuels.
For both applications, directed evolution is an essential tool to
identify improved variants.
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(15) Okamoto, Y.; Köhler, V.; Ward, T. R. An NAD(P)H-
Dependent Artificial Transfer Hydrogenase for Multienzymatic
Cascades. J. Am. Chem. Soc. 2016, 138, 5781−5784.
(16) Okamoto, Y.; Ward, T. R. Cross-Regulation of an Artificial
Metalloenzyme. Angew. Chem., Int. Ed. 2017, 56, 10156−10160.
(17) Jutz, G.; van Rijn, P.; Santos Miranda, B.; Böker, A. Ferritin: A
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(25) Tomaś-Gamasa, M.; Martínez-Calvo, M.; Couceiro, J. R.;
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